首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >Activation of dopamine D2 receptors in the CNS inhibits sympathetic cutaneous vasomotor alerting responses (SCVARs), contributing to clozapine's SCVAR-inhibiting action.
【24h】

Activation of dopamine D2 receptors in the CNS inhibits sympathetic cutaneous vasomotor alerting responses (SCVARs), contributing to clozapine's SCVAR-inhibiting action.

机译:中枢神经系统中多巴胺D2受体的激活抑制了交感性皮肤血管舒缩警报反应(SCVAR),有助于氯氮平的SCVAR抑制作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Sympathetic neural outflow to thermoregulatory cutaneous vascular beds is selectively activated when the individual is aroused, so that cutaneous blood flow is characterized by sudden alerting-related falls to near zero levels ("SCVARs", sympathetic cutaneous vasomotor alerting responses). Our previous work shows that clozapine, an atypical antipsychotic drug used in schizophrenia, profoundly inhibits SCVARs. Clozapine, conventionally assumed to have a dopamine D(2) receptor antagonist action, also increases baseline cutaneous blood flow and lowers body temperature. However dopamine D(2) receptor agonists lower temperature, suggesting that a dopamine D(2)agonist action might also reduce SCVARs. The present study determined whether a dopamine D(2)agonist action contributes to clozapine's SCVAR-inhibiting effect. SCVARs were measured in conscious rats with a Doppler ultrasonic flow probe chronically implanted around the base of the artery, with probe wires passing subcutaneously to a headpiece. Doppler signals were monitored via a flexible connection between the headpiece and a swivel device in the roof of the cage. Apomorphine (0.1-0.5 mg/kg), quinpirole (0.05-0.25 mg/kg) and 7-OH-DPAT (0.02-0.5 mg/kg) dose-dependently reduced SCVARs. Pre-treatment with the dopamine receptor antagonist spiperone (20 microg/kg) but not the D(1) antagonist SCH-23390 or the peripheral dopamine D(2) antagonist domperidone, abolished this effect. Spiperone pre-treatment reduced the SCVAR-inhibiting action of clozapine (0.06-1.0 mg/kg). Chlorpromazine (0.1-10 mg/kg) also dose-dependently inhibited SCVARs, but this effect was not reduced by pre-treatment with spiperone. Mechanisms underlying clozapine's SCVAR-inhibiting effect include dopamine D(2) receptor agonism, not dopamine D(2) receptor antagonism, calling into question the mechanism of the drug's therapeutic action in schizophrenia.
机译:当引起个体时,有选择性的激活了向体温调节性皮肤血管床的交感神经外流,从而使皮肤血流的特征在于与警报有关的突然下降至接近零水平(“ SCVAR”,即交感性皮肤血管舒缩警报反应)。我们以前的工作表明,氯氮平是一种用于精神分裂症的非典型抗精神病药物,可显着抑制SCVAR。氯氮平通常被认为具有多巴胺D(2)受体拮抗作用,它也会增加基线皮肤血流量并降低体温。但是,多巴胺D(2)受体激动剂的温度较低,表明多巴胺D(2)激动剂的作用也可能降低SCVAR。本研究确定了多巴胺D(2)激动剂的作用是否有助于氯氮平的SCVAR抑制作用。在意识清醒的大鼠中,通过将多普勒超声流量探头长期植入动脉底部,并通过皮下探头将探头导线传递到头部,来测量SCVAR。多普勒信号通过机头与笼子顶部的旋转装置之间的柔性连接进行监控。阿扑吗啡(0.1-0.5 mg / kg),喹吡罗(0.05-0.25 mg / kg)和7-OH-DPAT(0.02-0.5 mg / kg)剂量依赖性降低SCVAR。用多巴胺受体拮抗剂spiperone(20 microg / kg)而不是D(1)拮抗剂SCH-23390或外周多巴胺D(2)拮抗剂多潘立酮进行的预处理消除了这种作用。螺per酮预处理降低了氯氮平的SCVAR抑制作用(0.06-1.0 mg / kg)。氯丙嗪(0.1-10 mg / kg)也剂量依赖性地抑制SCVAR,但是用spiperone预处理并不能降低这种作用。氯氮平的SCVAR抑制作用的潜在机制包括多巴胺D(2)受体激动作用,而不是多巴胺D(2)受体拮抗作用,这使该药物在精神分裂症中的治疗作用机理产生了疑问。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号